SurModics/SRDX

$26.63

0.91%
-
1D1W1MYTD1YMAX

About SurModics

Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.

Ticker

SRDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Gary Maharaj

Employees

376

Headquarters

Eden prairie, United States

SurModics Metrics

BasicAdvanced
$377.54M
Market cap
67.81
P/E ratio
$0.39
EPS
1.03
Beta
-
Dividend rate
$377.54M
1.03037
$39.41
$16.79
59.77K
4.844
3.967
24.104
24.104
32.072
5.84%
3.15%
4.81%
3.49%
67.812
2.732
3.091
7.309
38.278
35.65%
116.88%
11.81%

What the Analysts think about SurModics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
121.55% upside
High $75.00
Low $44.00
$26.63
Current price
$59.00
Average price target

SurModics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2.29% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$30.5M
9.32%
Net income
$-700K
-110.61%
Profit margin
-2.29%
-109.68%

SurModics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 186.49%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.40
$0.52
$0.53
-
-
Expected
-$0.51
$0.05
$0.19
-$0.30
-$0.32
Surprise
-21.31%
893.64%
186.49%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for SurModics stock?

SurModics (SRDX) has a market cap of $375.69M as of April 20, 2024.

What is the P/E ratio for SurModics stock?

The price to earnings (P/E) ratio for SurModics (SRDX) stock is 67.48 as of April 20, 2024.

Does SurModics stock pay dividends?

No, SurModics (SRDX) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next SurModics dividend payment date?

SurModics (SRDX) stock does not pay dividends to its shareholders.

What is the beta indicator for SurModics?

SurModics (SRDX) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the SurModics stock price target?

The target price for SurModics (SRDX) stock is $59, which is 122.73% above the current price of $26.49. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell SurModics stock

Buy or sell SurModics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing